A clinical study that has been recently conducted on Neprinol use to treat Multiple Sclerosis has produced some surprising results.

Multiple Sclerosis (MS) is a progressive disease that damages the nervous system and affects the spinal cord, brain and optic nerves.

Symptoms of MS include numbness, paralysis and possible blindness.  MS symptoms occur and disappear, sometimes reoccurring months later and MS is classified as an autoimmune disease.  Doctors are unsure as to why the body suddenly starts attacking itself, but it has something to do with genetic and environmental factors.

Neprinol contains several enzymes whose main job is to break down fibrin.  Fibrin plays a role in blood clotting and the formation of scars in the body.  Fibrin will accumulate on the damaged nerves of patients with MS after myelin breaks down.

Neprinol helps break down the fibrin in the blood which is shown to be beneficial in patients with MS.  Many patients suffering with MS have seen significant responses when taking Neprinol and it has even helped to restore neurological function in some patients.

For more information about Neprinol take a look at enzymus.com

By Lord Walton of Detchant – 2nd February 2011

Lord Walton of Detchant calls for clarity in determining how multiple sclerosis care will be commissioned, following proposed restructures to the health service.

Multiple sclerosis is a chronic disease of the central nervous system involving the brain, spinal cord and sometimes the optic nerves. it is the commonest neurological disease affecting adults, involving approximately two million people worldwide and about 100,000 people in the UK.

Symptoms vary in severity; sometimes the disease is progressive but more often it is a relapsing and remitting disorder, in that episodes of weakness, numbness or visual failure occur but then recover wholly or in part, only for further such events to occur at a later date, often resulting ultimately in progressive disability.

Since the introduction of interferons in treatment some 20 years ago, these drugs and many more discovered since have been shown to be effective in reducing the severity of symptoms, in promoting remission and in delaying progression of the disease, particularly in the relapsing and remitting variety of the condition. These are so-called ‘disease-modifying drugs’.

Unfortunately, recent evidence shows that only about 12 per cent of patients with multiple sclerosis in the UK are currently receiving these remedies, and a report published by the department of health on medicines’ usage ranked the UK 13 out of 14 comparative countries with regard to MS drugs.

This finding is not consistent with the ten-year national service framework launched by the government in 2005 relating to the treatment of long-term conditions, and it is clear that substantial improvement in the availability of these drugs is needed.

The department of health introduced a risk-sharing scheme, enabling manufacturers of these drugs to share the cost of providing them while research was undertaken over a period of ten years to ascertain their long-term cost-effectiveness. it is unclear how future MS services will be commissioned, as between the new National Health Commissioning Board and local GP consortia, and this also needs to be clarified.

Lord Walton of Detchant Kt TD MA MD DSc FRCP FMedSci is a former consultant neurologist and professor of neurology. He was elevated to the peerage in 1989 and sits as a crossbencher.